UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ERCC1 and clinical resistance to platinum-based therapy

Clinical cancer research, 2005-09, Vol.11 (17), p.6100-6102

Reed, Eddie

2005

Volltextzugriff (PDF)

ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling

PloS one, 2014-09, Vol.9 (9), p.e107142

2014

Volltextzugriff (PDF)

Validation of a venous thromboembolism risk assessment model in gynecologic oncology

Gynecologic oncology, 2014-07, Vol.134 (1), p.160-163

2014

Volltextzugriff (PDF)

Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer

PloS one, 2014-06, Vol.9 (6), p.e98370

2014

Volltextzugriff (PDF)

Apigenin inhibits VEGF and HIF‐1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways

The FASEB journal, 2005-03, Vol.19 (3), p.342-353

2005

Volltextzugriff (PDF)

Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review)

Oncology reports, 2004-11, Vol.12 (5), p.955

2004

Volltextzugriff (PDF)

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Journal of clinical oncology, 1999-11, Vol.17 (11), p.3461-3467

1999

Volltextzugriff (PDF)

A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-independent Prostate Cancer

Clinical cancer research, 2001-07, Vol.7 (7), p.1888-1893

2001

Volltextzugriff (PDF)

DNA Damage and Repair in Translational Oncology: An Overview

Clinical cancer research, 2010-09, Vol.16 (18), p.4511-4516

REED, Eddie

2010

Volltextzugriff (PDF)

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel

Biochemical pharmacology, 1996-12, Vol.52 (12), p.1855-1865

1996

Volltextzugriff (PDF)

Translational Nucleotide Excision Repair in Triple Negative Breast Cancer

The FASEB journal, 2013-04, Vol.27 (S1)

Reed, Eddie

2013

Volltextzugriff (PDF)

Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer

Cancer biology & therapy, 2010-07, Vol.10 (1), p.13-18

2010

Volltextzugriff (PDF)

Correlation of Serum VEGF Levels with Clinical Stage, Therapy Efficacy, Tumor Metastasis and Patient Survival in Ovarian Cancer

Anticancer research, 2004-05, Vol.24 (3B), p.1973-1979

2004

Volltextzugriff (PDF)

BRCA1 Contributes to Cell Cycle Arrest and Chemoresistance in Response to the Anticancer Agent Irofulven

Molecular pharmacology, 2007-04, Vol.71 (4), p.1051-1060

2007

Volltextzugriff (PDF)

ERCC1 Measurements in Clinical Oncology

The New England journal of medicine, 2006-09, Vol.355 (10), p.1054-1055

Reed, Eddie

2006

Volltextzugriff (PDF)

Clear Cell Tumors Have Higher mRNA Levels of ERCC1 and XPB Than Other Histological Types of Epithelial Ovarian Cancer

Clinical cancer research, 2003-11, Vol.9 (14), p.5299-5305

2003

Volltextzugriff (PDF)

When chronic conditions become acute: prevention and control of chronic diseases and adverse health outcomes during natural disasters

Preventing chronic disease, 2005-11, Vol.2 Spec no (Spec No), p.A04-A04

2005

Volltextzugriff (PDF)

Duration of Cisplatin Excretion in Breast Milk

Journal of human lactation, 2013-11, Vol.29 (4), p.469-472

2013

Volltextzugriff (PDF)

Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer

Journal of clinical oncology, 2003-12, Vol.21 (23), p.4356-4363

2003

Volltextzugriff (PDF)

CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer

Molecular cancer, 2004-05, Vol.3 (1), p.14-14

2004

Volltextzugriff (PDF)

Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

Journal of clinical oncology, 2001-01, Vol.19 (2), p.584-592

2001

Volltextzugriff (PDF)

Epothilones: a novel class of non-taxane microtubule-stabilizing agents

Current pharmaceutical design, 2002-01, Vol.8 (19), p.1707-1712

2002

Volltextzugriff (PDF)

Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven

Molecular cancer therapeutics, 2006-12, Vol.5 (12), p.3153-3161

2006

Volltextzugriff (PDF)

CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival

Clinical & experimental metastasis, 2012-12, Vol.29 (8), p.939-948

2012

Volltextzugriff (PDF)

ATM-dependent CHK2 Activation Induced by Anticancer Agent, Irofulven

The Journal of biological chemistry, 2004-09, Vol.279 (38), p.39584-39592

2004

Volltextzugriff (PDF)

1 – 25 von 297

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(262)
Mit Volltextzugriff
(244)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ERCC1 and clinical resistance to platinum-based therapy

ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling

Validation of a venous thromboembolism risk assessment model in gynecologic oncology

Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer

Apigenin inhibits VEGF and HIF‐1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways

Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review)

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-independent Prostate Cancer

DNA Damage and Repair in Translational Oncology: An Overview

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel

Translational Nucleotide Excision Repair in Triple Negative Breast Cancer

Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer

Correlation of Serum VEGF Levels with Clinical Stage, Therapy Efficacy, Tumor Metastasis and Patient Survival in Ovarian Cancer

BRCA1 Contributes to Cell Cycle Arrest and Chemoresistance in Response to the Anticancer Agent Irofulven

ERCC1 Measurements in Clinical Oncology

Clear Cell Tumors Have Higher mRNA Levels of ERCC1 and XPB Than Other Histological Types of Epithelial Ovarian Cancer

When chronic conditions become acute: prevention and control of chronic diseases and adverse health outcomes during natural disasters

Duration of Cisplatin Excretion in Breast Milk

Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer

CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer

Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

Epothilones: a novel class of non-taxane microtubule-stabilizing agents

Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven

CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival

ATM-dependent CHK2 Activation Induced by Anticancer Agent, Irofulven

Suchergebnisse filtern